Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by PsychoGenics Inc..
Recruitment status was  Recruiting
Information provided by (Responsible Party):
PsychoGenics Inc.
ClinicalTrials.gov Identifier:
First received: December 21, 2010
Last updated: May 2, 2012
Last verified: May 2012

The purpose of this study is to determine if eltoprazine (as an adjunct to anti-psychotic medication) improves one or more aspects of cognitive impairment in adult schizophrenic patients.

Condition Intervention Phase
Cognitive Impairment
Drug: Eltoprazine
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia

Resource links provided by NLM:

Further study details as provided by PsychoGenics Inc.:

Primary Outcome Measures:
  • MATRICS Consensus Cognitive Battery (MCCB) [ Time Frame: At Baseline and every 4 weeks ] [ Designated as safety issue: No ]
    Assessment of cognitive effects over time measured suing the MCCB battery

Secondary Outcome Measures:
  • Continuous Performance Test-AX Version (CPT-AX) [ Time Frame: At Baseline and every 4 weeks ] [ Designated as safety issue: No ]
    Assessment of Cognitive effects over time measured using the Continuous Performance Test (AX version)

  • N-Back [ Time Frame: At Baseline and every 4 weeks ] [ Designated as safety issue: No ]
    Assessment of Cognitive effects over time measured using the N-Back Working Memory Test

  • Brief Psychiatric Rating Scale (BPRS) [ Time Frame: At Baseline and every 2 weeks ] [ Designated as safety issue: No ]
  • Calgary Depression Scale (CDS) [ Time Frame: At Baseline and every 2 weeks ] [ Designated as safety issue: No ]
  • Scale for Assessment of Negative Symptoms (SANS) [ Time Frame: At Baseline and every 2 weeks ] [ Designated as safety issue: No ]
  • Simpson-Angus Extrapyramidal Symptom Rating Scale (SAS) [ Time Frame: At Baseline and every 2 weeks ] [ Designated as safety issue: Yes ]
  • Abnormal Involuntary Movement Scale (AIMS) [ Time Frame: At Baseline and every 2 weeks ] [ Designated as safety issue: Yes ]
  • Barnes Akathisia Scale (BAS) [ Time Frame: At Baseline and every 2 weeks ] [ Designated as safety issue: Yes ]
  • Columbia Suicide Severity Rating Scale (C-SSRS) [ Time Frame: At baseline and end of study; every two weeks if there is a change in the CDRS suicidality rating to a score of 2 or 3 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: August 2011
Estimated Study Completion Date: November 2012
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eltoprazine Drug: Eltoprazine
Comparison of eltoprazine, dosed orally, for 8 weeks
Placebo Comparator: Placebo Drug: Placebo
Placebo to match eltoprazine

Detailed Description:

Schizophrenia is a common and highly disabling psychiatric disorder with population prevalence around 1%. The manifestations of schizophrenia fall into three major domains: 1) "positive" symptoms, such as delusions, hallucinations, and disorganization of behavior; 2) "negative symptoms," including social withdrawal, lack of motivation, and reduced expression of affect; and 3) cognitive dysfunction. Cognitive deficits are seen in most patients with schizophrenia.

Eltoprazine has agonist effects on both 5-HT1A and 5-HT1B receptors, which suggests that this drug may be useful for normalizing prefrontal cognitive abilities, reducing aggression and impulsivity, and improving cognitive function in schizophrenia.

This study will compare the effects of Eltoprazine (as an adjunctive treatment to anti-psychotics) with Placebo in Adults with a DSM IV/DSM IV TR diagnosis of schizophrenia, in potentially improving one or more dimensions of cognitive impairment associated with schizophrenia.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and Females, 18-65 years of age, inclusive, who meet the DSM-IV-TR criteria for schizophrenia.
  • Must test negative for pregnancy at the time of enrollment based on a serum pregnancy test and agrees to use a reliable method of birth control during the study.
  • Performance less than the maximum cutoff (in parentheses) for ONE of the following MATRICS Consensus Cognitive Battery (MCCB tests: i) Letter-number span (20); ii) HVLT total (31); and iii) CPT d-prime (3.47)
  • Brief Psychiatric Rating Scale (BPRS) Hallucinatory Behavior or Unusual Thought Content item scores ≤ 5
  • BPRS Conceptual Disorganization item score ≤ 4
  • Simpson-Angus Scale total score ≤ 6
  • Calgary Depression Rating Scale (CDRS) total score ≤ 10
  • Able to complete the baseline MCCB validly as assessed by Chief Neuropsychologist or tester
  • Wechsler Test of Adult Reading (WTAR) raw score ≥ 6
  • Be treated with one of the following second generation antipsychotics: risperidone, olanzapine, quetiapine, asenapine, iloperidone or paliperidone for the previous two months, with no change in dose in the last month, or with injectable depot antipsychotics (fluphenazine, haloperidol decanoate, risperdal Consta or paliperidone sustenna) with no change in last 3 months
  • Laboratory results must show no clinically significant abnormalities.
  • Must have an electrocardiogram (ECG) with QTc measurement performed at Screening that is not clinically significant.
  • Must have a negative drug screen.

Exclusion Criteria:

  • Current treatment with one of the following antipsychotics: clozapine, aripiprazole, lurasidone or ziprasidone.
  • Current treatment with any anti-cholinergic drug in doses above 2 mg daily for benztropine, 5 mg per day for trihexyphenidyl, and 50 mg day for diphenhydramine.
  • Current treatment with benzodiazepines in doses above 10 mg of diazepam (or the equivalent of another drug).
  • Patients with a DSM-IV diagnosis of alcohol or substance abuse (other than nicotine) within the last month or a DSM-IV diagnosis of alcohol or substance dependence (other than nicotine) within the last 6 months.
  • Have a significant suicide attempt within one year of Visit 1, answered yes to question 3, 4 or 5 on the C-SSRS (screening form) at Visit 1, or are currently at risk of suicide in the opinion of the Investigator.
  • Patients with a history of significant head injury/trauma.
  • Patients with a clinically significant neurological, metabolic, hepatic, hematological, pulmonary, cardiovascular, gastrointestinal, and/or urological disorder. Insulin-dependent diabetics who are clinically stable and whose baseline fasting glucose is 200 or less may be included.
  • Clinically significant abnormalities in physical examination, ECG, or laboratory assessments.
  • Clinically significant renal disease (e.g. chronic renal insufficiency with Glomerular filtration rate (GFR) <60, inflammatory disease requiring medication, acute renal failure).
  • Pregnant women or women of child-bearing potential, who are either not surgically-sterile or using appropriate methods of birth control.
  • Women who are breast-feeding
  • Have a thyroid stimulating hormone (TSH) level consistent with hyperthyroidism or hypothyroidism. Patients previously diagnosed with hyperthyroidism or hypothyroidism, who have been treated on a stable dose of thyroid supplement for at least the past 3 months, and who are clinically and chemically euthyroid will be allowed to participate in the study.
  • Have significant prior or current medical conditions that, in the judgment of the investigator, could be exacerbated by or compromised by study drug.
  • Have any medical condition that would increase sympathetic nervous system activity markedly. Patients who are taking a medication on a daily basis (for example, albuterol, inhalation aerosols, pseudoephedrine), that has sympathomimetic activity can be enrolled.
  • Used monoamine oxidase inhibitors (MAOIs) during the 2 weeks (14 days) prior to Baseline Visit 1.
  • Have used any SSRI, a 5HT1A agonist or other serotonin-mediated treatment for any reason during the 4 weeks prior to Baseline Visit 1.
  • Have current hypertension despite treatment.
  • Have received treatment within the last 60 days with a drug that has not received regulatory approval for any indication at the time of study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01266174

United States, California
Veteran's Administration of Greater Los Angeles Recruiting
Los Angeles, California, United States, 90073
Contact: Michael H DeGroot    310-562-9578    mdegroot@mednet.ucla.edu   
Contact: Christen M Waldon    310-478-3711 ext 49234      
Principal Investigator: Stephen Marder, MD         
United States, Illinois
Northwestern University Feinberg School of Medicine Recruiting
Chicago, Illinois, United States, 60611
Contact: pamela voss    312-695-2203      
Principal Investigator: John G Csernansky, MD         
United States, Maryland
Maryland Psychiatric Research Center Recruiting
Catonsville, Maryland, United States, 21228
Contact: Pat Ball    410-402-7663    pball@mprc.umaryland.edu   
Contact: Jen Osing    410-402-6060    josing@mprc.umaryland.edu   
Principal Investigator: Robert W Buchanan, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Ryan Maher    617-912-7893    trmaher@partners.org   
Contact: Tim Creedon    617-912-7864      
Principal Investigator: Oliver Freudenreich         
United States, New York
Research Foundation for Mental Hygiene, Inc. Recruiting
New York, New York, United States, 10032
Contact: Marlene Carlson    212-543-5678    mc157@columbia.edu   
Principal Investigator: Jeffrey Lieberman, MD         
United States, North Carolina
Duke University School of Medicine Recruiting
Durham, North Carolina, United States, 27705
Contact: Leslie Yusko    919-575-7364      
Contact: Miriam McKenzie    919-575-2634    mhm3@duke.edu   
Principal Investigator: Joseph P McEvoy, MD         
Sponsors and Collaborators
PsychoGenics Inc.
Principal Investigator: John G Csernansky, MD NortWestern University Feinberg School of Medicine
  More Information

No publications provided

Responsible Party: PsychoGenics Inc.
ClinicalTrials.gov Identifier: NCT01266174     History of Changes
Other Study ID Numbers: PGI12004
Study First Received: December 21, 2010
Last Updated: May 2, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by PsychoGenics Inc.:

Additional relevant MeSH terms:
Schizophrenia and Disorders with Psychotic Features
Cognition Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Serotonin Agents
Serotonin Receptor Agonists

ClinicalTrials.gov processed this record on March 25, 2015